145 related articles for article (PubMed ID: 37757536)
21. Interferons and their role In inflammation.
Tilg H; Kaser A
Curr Pharm Des; 1999 Oct; 5(10):771-85. PubMed ID: 10526087
[TBL] [Abstract][Full Text] [Related]
22. Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.
Green DS; Husain SR; Johnson CL; Sato Y; Han J; Joshi B; Hewitt SM; Puri RK; Zoon KC
Immunotherapy; 2019 Apr; 11(6):483-496. PubMed ID: 30860437
[TBL] [Abstract][Full Text] [Related]
23. Emerging roles of IL-34 in neurodegenerative and neurological infectious disease.
Chhetri G
Int J Neurosci; 2023 Jun; 133(6):660-671. PubMed ID: 34347576
[TBL] [Abstract][Full Text] [Related]
24. Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19.
Fietta P; Costa E; Delsante G
Theor Biol Forum; 2014; 107(1-2):13-45. PubMed ID: 25936211
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression.
Endo H; Hama N; Baghdadi M; Ishikawa K; Otsuka R; Wada H; Asano H; Endo D; Konno Y; Kato T; Watari H; Tozawa A; Suzuki N; Yokose T; Takano A; Kato H; Miyagi Y; Daigo Y; Seino KI
Int Immunol; 2020 Mar; 32(3):175-186. PubMed ID: 31868884
[TBL] [Abstract][Full Text] [Related]
26. Interleukine-10 in ovarian cancer.
Levin G; Gotlieb WH
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38735685
[TBL] [Abstract][Full Text] [Related]
27. Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway.
Massa C; Wang Y; Marr N; Seliger B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047709
[TBL] [Abstract][Full Text] [Related]
28. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
29. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
30. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells.
Tanemura S; Tsujimoto H; Seki N; Kojima S; Miyoshi F; Sugahara K; Yoshimoto K; Suzuki K; Kaneko Y; Chiba K; Takeuchi T
Int Immunol; 2022 Sep; 34(10):519-532. PubMed ID: 35723683
[TBL] [Abstract][Full Text] [Related]
31. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
Chyuan IT; Tzeng HT; Chen JY
Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
[TBL] [Abstract][Full Text] [Related]
32. Role of interferons (IFNs) in the differentiation of T peripheral helper (Tph) cells.
Tanemura S; Seki N; Tsujimoto H; Saito S; Kikuchi J; Sugahara K; Yoshimoto K; Suzuki K; Kaneko Y; Chiba K; Takeuchi T
Int Immunol; 2022 Sep; 34(10):533-544. PubMed ID: 35780437
[TBL] [Abstract][Full Text] [Related]
33. Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells.
Tezuka Y; Endo S; Matsui A; Sato A; Saito K; Semba K; Takahashi M; Murakami T
Lung Cancer; 2012 Dec; 78(3):185-92. PubMed ID: 23021208
[TBL] [Abstract][Full Text] [Related]
34. IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.
Batchu RB; Gruzdyn OV; Kolli BK; Dachepalli R; Umar PS; Rai SK; Singh N; Tavva PS; Weaver DW; Gruber SA
Adv Exp Med Biol; 2021; 1290():51-65. PubMed ID: 33559854
[TBL] [Abstract][Full Text] [Related]
35. Role of Type I and II Interferons in Colorectal Cancer and Melanoma.
Di Franco S; Turdo A; Todaro M; Stassi G
Front Immunol; 2017; 8():878. PubMed ID: 28798748
[TBL] [Abstract][Full Text] [Related]
36. Interferon: cellular executioner or white knight?
Maher SG; Romero-Weaver AL; Scarzello AJ; Gamero AM
Curr Med Chem; 2007; 14(12):1279-89. PubMed ID: 17504213
[TBL] [Abstract][Full Text] [Related]
37. Type I interferons in the pathogenesis and treatment of canine diseases.
Klotz D; Baumgärtner W; Gerhauser I
Vet Immunol Immunopathol; 2017 Sep; 191():80-93. PubMed ID: 28895871
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune Neuroinflammatory Diseases: Role of Interleukins.
Khan AW; Farooq M; Hwang MJ; Haseeb M; Choi S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175665
[TBL] [Abstract][Full Text] [Related]
39. Safety, Tolerability, and Immunogenicity of Interferons.
Tovey MG; Lallemand C
Pharmaceuticals (Basel); 2010 Apr; 3(4):1162-1186. PubMed ID: 27713294
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γ.
Petanidis S; Anestakis D; Argyraki M; Hadzopoulou-Cladaras M; Salifoglou A
PLoS One; 2013; 8(9):e73616. PubMed ID: 24040001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
